Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined large and small airway obstruction is associated with increased exacerbation frequency and poorer symptom control in persistent asthma.

The journal of allergy and clinical immunology. In practice·2026
Same author

Prioritising efficacy over convenience.

American journal of respiratory and critical care medicine·2026
Same author

Single-cell transcriptomics of granulocytes in asthma and atopic diseases.

Frontiers in molecular biosciences·2026
Same author

Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study.

American journal of respiratory and critical care medicine·2026
Same author

Temporal dynamics of mental defeat in chronic pain: a longitudinal network analysis of ecological momentary assessment data.

Pain·2026
Same author

Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial.

Nature medicine·2026
Same journal

A Retrospective Case Series of Unusual Natural History Phenotypes of Food Protein-Induced Enterocolitis.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same journal

Anaphylactic Shock Due to Contaminated Albuterol Nebulizer with an Asian Lady Beetle (Harmonia axyridis): A Case Report.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same journal

Associations between genetic ancestry and allergic outcomes at 10 years among Black children.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same journal

Five-Year Follow-up After Peach Sublingual Immunotherapy in LTP Syndrome.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same journal

Overlapping Mechanisms and Novel Biomarkers Define Asthma and COPD as a Spectrum of Airway Disease.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same journal

Real-World Variation in Post-Dose Supervision and Activity Restriction During Maintenance Cow's Milk Oral Immunotherapy.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
See all related articles

Related Experiment Videos

Biomarkers for COPD with Type 2 Inflammation.

Chetna Pathak1, Joshua Cox2, Rajat Suri3

  • 1Division of Pulmonary, Critical Care, Sleep Medicine and Physiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA; Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, CA, USA.

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|June 27, 2026
PubMed
Summary
This summary is machine-generated.

Type 2 (T2) inflammation, characterized by eosinophils, affects 20-40% of COPD patients. Identifying this endotype with biomarkers like blood eosinophil count (BEC) enables targeted therapies for better outcomes.

Keywords:
COPD biomarkersEosinophilic COPDType 2 Inflammationblood eosinophil countepithelial alarmins

Related Experiment Videos

Area of Science:

  • Pulmonology
  • Immunology
  • Precision Medicine

Background:

  • Chronic obstructive pulmonary disease (COPD) is heterogeneous, with 20-40% exhibiting a Type 2 (T2) inflammatory endotype.
  • T2 inflammation involves Th2 cells, innate lymphoid cells, and cytokines IL-4, IL-5, IL-13, leading to eosinophilic infiltration and airway changes.

Purpose of the Study:

  • To review the pathophysiology and clinical impact of T2 inflammation in COPD.
  • To highlight biomarkers for identifying T2-high COPD and guiding targeted treatments.

Main Methods:

  • Review of existing literature on T2 inflammation in COPD.
  • Focus on biomarkers such as blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO), and serum IgE.
  • Examination of clinical trial data for T2-targeted therapies.

Main Results:

  • T2 inflammation in COPD is linked to increased exacerbations and faster lung function decline.
  • BEC is a validated biomarker; FeNO and serum IgE offer complementary value.
  • Biologics targeting T2 pathways show therapeutic potential in selected COPD patients.

Conclusions:

  • Identifying T2-high COPD via biomarkers is crucial for precision medicine.
  • Targeting T2 inflammation offers a promising strategy for managing a significant COPD subgroup.
  • Further research is needed to optimize T2-targeted therapies and address knowledge gaps.